

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Search strategy

Database	Search terms
PubMed	(((covid-19 OR sars-cov-2) AND vaccin*) OR sars-cov-2 vaccine) AND (pemphig* OR duhring disease OR epidermolysis bullosa acquisita OR linear iga OR iga dermatosis OR iga dermat* OR autoimmune bullous disease OR autoimmune blistering disease OR psoria* OR urticaria OR urticar* OR atopic eczema OR ((dermatitis OR dermat*) AND atopic) OR lupus erythematosus)
Scopus	TITLE-ABS-KEY (((("sars-cov-2" OR "covid-19") AND "vaccin*") AND ("pemphig*" OR "duhring disease" OR "dermatitis herpetiformis" OR "epidermolysis bullosa acquisita" OR "linear iga" OR "iga dermat*" OR "autoimmune bullous disease" OR "autoimmune blistering disease" OR "psoria*" OR "urticar*" OR "atopic dermat*" OR "atopic eczema" OR "lupus"))
Embase	(('coronavirus disease 2019'/exp OR 'coronavirus disease 2019' OR 'covid 19'/exp OR 'covid 19' OR 'sars cov 2'/exp OR 'sars cov 2') AND ('vaccine'/exp OR vaccine OR vaccin*) OR 'sars-cov-2 vaccine'/exp OR 'sars-cov-2 vaccine') AND ('pemphigus'/exp OR pemphigus OR 'pemphigoid'/exp OR pemphigoid OR pemphig* OR 'dermatitis herpetiformis'/exp OR 'dermatitis herpetiformis' OR 'epidermolysis bullosa acquisita'/exp OR 'epidermolysis bullosa acquisita' OR 'linear iga bullous dermatosis'/exp OR 'linear iga bullous dermatosis' OR 'adult linear iga disease'/exp OR 'adult linear iga disease' OR 'linear iga' OR (linear AND ('iga'/exp OR iga)) OR (('iga'/exp OR iga) AND dermat*) OR 'autoimmune bullous disease'/exp OR 'autoimmune bullous disease' OR 'autoimmune blistering disease'/exp OR 'autoimmune blistering disease' OR 'psoriasis'/exp OR psoriasis OR 'urticaria'/exp OR urticaria OR urticar* OR 'atopic dermatitis'/exp OR 'atopic dermatitis' OR 'atopic eczema'/exp OR 'atopic eczema' OR 'lupus erythematosus'/exp OR 'lupus erythematosus')

Table SII. Conversion factors for the BAU/mL unit recommended by the WHO international standard for anti-SARS-CoV-2 immunoglobulin

Manufacturers	Unit	Conversion factors
Abbott (US)	AU/ml	0.142
LIAISON (Italy)	AU/ml	2.6
Roche (Switzerland)	U/ml	1.029

BAU: binding antibody units; AU: arbitrary units; U: units

Table SIII. Risk of bias assessment with the Newcastle-Ottawa scale

First author (year)	Selection (Question 1-4)	Comparability (Question 5)	Outcomes (Question 6-8)	Total score	Quality rating
Boekel (2022)	3	0	3	6	Moderate
Stalman (2022)	3	0	2	5	Moderate
Cao (2022)	2	0	2	4	High
Chanprapaph (2022)	4	1	3	8	Low
Cristaudo (2022)	4	2	3	9	Low
Özgen (2022)	4	0	3	7	Low
Mahil (2021) (27)	4	0	3	7	Low
Mahil (2021) (28)	4	0	3	7	Low
Megna (2022)	3	1	3	7	Low
Pakhchanian (2022)	4	0	4	8	Low
Parlotsky (2022)	3	0	3	6	Moderate
Piros (2022)	4	1	3	8	Low
Seree-aphinan (2021)	4	1	3	8	Low

